Transport of iron chelators and chelates across MDCK cell monolayers: Implications for iron excretion during chelation therapy

International Journal of Hematology

Volumn 91, Issue 3, 2010, Pages 401-412

  Huang, Xi Ping ^a   Thiessen, Jake J ^a   Spino, Michael ^a,b   Templeton, Douglas M ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ApoPharma Inc   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chelator transport; Iron chelates; MDCK cell monolayer; Polarized epithelia; Renal reabsorption

Indexed keywords

ADENOSINE TRIPHOSPHATE; CP 363; CP 502; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; IRON 59; IRON CHELATE; IRON CHELATING AGENT; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL STRAIN; CONTROLLED STUDY; DIFFUSION; DRUG STRUCTURE; DRUG TRANSPORT; EPITHELIUM CELL; IRON CHELATION; IRON OVERLOAD; IRON TRANSPORT; KIDNEY EPITHELIUM; KIDNEY TUBULE ABSORPTION; MONOLAYER CULTURE; NEPHROTOXICITY; NONHUMAN; TEMPERATURE DEPENDENCE; TEMPERATURE SENSITIVITY; TRANSPORT KINETICS; URINARY EXCRETION;

ADENOSINE TRIPHOSPHATE; ANIMALS; BENZOIC ACIDS; BIOLOGICAL TRANSPORT; CELL LINE; CELL POLARITY; DEFEROXAMINE; DOGS; EPITHELIAL CELLS; EXOCYTOSIS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; IRON RADIOISOTOPES; KIDNEY; MODELS, BIOLOGICAL; PYRIDONES; SIDEROPHORES; TEMPERATURE; TRIAZOLES;

EID: 77950918117     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0510-3     Document Type: Article

References (61)

1. MB Agarwal C Viswanathan J Ramanathan DE Massil S Shah SS Gupte, et al. 1990 Oral iron chelation with L1 Lancet 335 601 10.1016/0140-6736(90)90380-N 1:STN:280:DyaK3c7ntlKitw%3D%3D 1968588 (Pubitemid 20089269)
2. AV Hoffbrand 2005 Deferiprone therapy for transfusional iron overload Best Pract Res Clin Haematol. 18 299 317 10.1016/j.beha.2004.08.026 (Pubitemid 40298372)
3. C Borgna-Pignatti MD Cappellini P De Stefano GC Del Vecchio GL Forni MR Gamberini, et al. 2006 Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major Blood 107 3733 3737 10.1182/blood-2005-07-2933 1:CAS:528:DC%2BD28Xkt1Giu7k%3D 16373663
4. DJ Pennel V Berdoukas M Karagiorga V Ladis A Piga A Aessopos, et al. 2006 Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis Blood 107 3738 3744 10.1182/blood-2005-07-2948
5. S Singh RO Epemolu PS Dobbin GS Tilbrook BL Ellis LA Damani, et al. 1992 Urinary metabolic profiles in human and rat of 1, 2-dimethyl- and 1, 2-diethyl substituted 3-hydroxypyridin-4-ones Drug Metab Disposit. 20 256 261 1:CAS:528:DyaK38XisVOrsLw%3D
6. A Taher FM Chamoun S Koussa MA Saad AI Khoriaty R Neeman, et al. 1999 Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine Acta Haematol. 101 173 177 10.1159/000040949 1:CAS:528:DyaK1MXkvF2ltrk%3D 10436297 (Pubitemid 29348597)
7. AR Cohen R Galanello A Piga V De Sanctis F Tricta 2003 Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone Blood 102 1583 1587 10.1182/blood-2002-10-3280 1:CAS:528:DC%2BD3sXntFartLY%3D 12763939 (Pubitemid 37022545)
8. M Franchini D Veneri 2004 Iron-chelation therapy: an update Hematol J. 5 287 292 10.1038/sj.thj.6200407 1:CAS:528:DC%2BD2cXmtlSjurc%3D 15297844 (Pubitemid 39214205)
9. R Galanello A Piga D Alberti MC Rouan H Bigler R Sechaud 2003 Safety, tolerability, and pharmacokinetics of ICL670, an new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia J Clin Pharmacol. 43 565 572 1:CAS:528:DC%2BD3sXkslGhsLk%3D 12817519 (Pubitemid 36613115)
10. C Hershko 2005 Treating iron overload: the state of the art Semin Hematol. 42 S2 S4 10.1053/j.seminhematol.2005.01.003 1:CAS:528: DC%2BD2MXksFCksbk%3D 15846582 (Pubitemid 40410476)
11. LP Yang SJ Keam GM Keating 2007 Deferasirox: a review of its use in the management of transfusional chronic iron overload Drugs. 67 2211 2230 10.2165/00003495-200767150-00007 1:CAS:528:DC%2BD2sXhsVWkt7fM 17927285
12. E Vichinsky 2008 Clinical application of deferasirox: practical patient management Am J Hematol. 83 398 402 10.1002/ajh.21119 1:CAS:528: DC%2BD1cXmvVSgtrc%3D 18058997 (Pubitemid 351614754)
13. A Maggio 2007 Light and shadows in the iron chelation treatment of haematological diseases Br J Haematol. 138 407 421 10.1111/j.1365-2141.2007. 06666.x 1:CAS:528:DC%2BD2sXhtVehs77E 17659052 (Pubitemid 47063024)
14. M Wareing CJ Ferguson R Green D Riccardi CP Smith 2000 In vivo characterization of renal iron transport in the anaesthetized rat J Physiol 524 581 586 10.1111/j.1469-7793.2000.00581.x 1:CAS:528:DC%2BD3cXjsVWmurc%3D 10766935 (Pubitemid 30229520)
15. CJ Ferguson M Wareing M Delannoy R Fenton SJ McLarnon N Ashton, et al. 2003 Iron handling and gene expression of the divalent metal transporter, DMT1, in the kidney of the anemic Belgrade (b) rat Kidney Int 64 1755 1764 10.1046/j.1523-1755.2003.00274.x 1:CAS:528:DC%2BD3sXpsVCrt70%3D 14531808 (Pubitemid 37323704)
16. M Wareing CJ Ferguson M Delannoy AG Cox RF McMahon R Green, et al. 2003 Altered dietary iron intake is a strong modulator of renal DMT1 expression Am J Physiol 285 F1050 F1059 1:CAS:528:DC%2BD2cXhsVyq (Pubitemid 37421040)
17. H Gunshin B Mackenzie UV Berger Y Gunshin MF Romero WF Boron, et al. 1997 Cloning and characterization of a mammalian proton-coupled metal-ion transporter Nature. 388 482 488 10.1038/41343 1:CAS:528:DyaK2sXltFGqtbY%3D 9242408 (Pubitemid 27328927)
18. CJ Ferguson M Wareing DT Ward R Green CP Smith D Riccardi 2001 Cellular localization of divalent metal transporter DMT-1 in rat kidney Am J Physiol 280 F803 F814 1:CAS:528:DC%2BD3MXjsVCjsrc%3D (Pubitemid 32441255)
19. FS Canonne-Hergaux P Gros 2002 Expression of the iron transporter DMT1 in kidney from normal and anemic mk mice Kidney Int 62 147 156 10.1046/j.1523-1755.2002.00405.x 1:CAS:528:DC%2BD38XlsFyqurg%3D 12081573 (Pubitemid 34754057)
20. M Abouhamed J Gburek W Liu B Torchalski A Wilhelm NA Wolff, et al. 2006 Divalent metal transporter 1 in the kidney proximal tubule is expressed in late endosomes/lysosomal membranes: implications for renal handling of protein-metal complexes Am J Physiol 290 F1525 F1533 10.1152/ajprenal.00359.2005 1:CAS:528:DC%2BD28XlvVertrk%3D (Pubitemid 43830780)
21. AC Alfrey WS Hammond 1990 Renal iron handling in the nephrotic syndrome Kidney Int 37 1409 1413 10.1038/ki.1990.130 1:CAS:528:DyaK3cXmtV2gsb4%3D 2362400 (Pubitemid 20198021)
22. AC Alfrey 1992 Toxicity of tubule fluid iron in the nephrotic syndrome Am J Physiol 263 F637 F641 1:CAS:528:DyaK38XmsV2mtbs%3D 1384359
23. R Kozyraki J Fyfe PJ Verroust C Jacobsen A Dautry-Varsat J Gburek, et al. 2001 Megalin-dependent cubilin-mediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia Proc Natl Acad Sci USA 98 12491 12496 10.1073/pnas.211291398 1:CAS:528:DC%2BD3MXotFaitLk%3D 11606717 (Pubitemid 33019973)
24. J Yang K Mori JY Li J Barasch 2003 Iron, lipocalin, and kidney epithelia Am J Physiol 285 F9 F18 1:CAS:528:DC%2BD3sXlsFGhsLc%3D (Pubitemid 36818457)
25. M Cereijido ES Robbins WJ Dolan CA Rotunno DD Sabatini 1978 Polarized monolayers formed by epithelial cells on a permeable and translucent support J Cell Biol 77 853 880 10.1083/jcb.77.3.853 1:CAS:528:DyaE1cXkt1Wgsro%3D 567227 (Pubitemid 8347746)
26. TF Tam R Leung-Toung W Li Y Wang K Karimian M Spino 2003 Iron chelator research: past, present, and future Curr Med Chem 10 983 995 10.2174/0929867033457593 1:CAS:528:DC%2BD3sXjs1yjtLY%3D 12678671 (Pubitemid 36582243)
27. JG Parkes DM Templeton 1994 Iron transport and subcellular distribution in Hep G2 hepatocarcinoma cells Ann Clin Lab Sci 24 509 521 1:CAS:528: DyaK2MXitFWqs78%3D 7847779
28. A Tesoro J Novakovic JJ Thiessen M Spino 2005 Validated HPLC assay for iron determination in biological matrices based on ferrioxamine formation J Chromatogr B. 823 177 183 10.1016/j.jchromb.2005.06.033 1:CAS:528: DC%2BD2MXns1Wntr8%3D (Pubitemid 41116761)
29. McManus JFA, Mowry RW. Staining methods. Histological and histochemical. 1960, New York: Paul B. Hober, pp 195-7.
30. JG Parkes Y Liu JB Sirna DM Templeton 2000 Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts J Mol Cell Cardiol 32 233 246 10.1006/jmcc.1999.1068 1:CAS:528: DC%2BD3cXhvVCgsL0%3D 10722800 (Pubitemid 30670346)
31. K Sandvig A Llorente SK Rodal P Eker O Garred M Stahlhut, et al. 2000 Apical macropinocytosis in polarized MDCK cells: regulation by N-ethylmaleimide-sensitive proteins Eur J Cell Biol 79 447 457 10.1078/0171-9335-00071 1:CAS:528:DC%2BD3cXmslSgu7g%3D 10961444 (Pubitemid 30612200)
32. I Nunes-Correia A Eulalio S Nir MC Pedroso de Lima 2004 Caveolae as an additional route for influenza virus endocytosis in MDCK cells Cell Mol Biol Lett. 9 47 60 15048150 (Pubitemid 38560196)
33. XP Huang M Spino JJ Thiessen 2006 Transport kinetics of iron chelators and their chelates in Caco-2 cells Pharm Res 23 280 290 10.1007/s11095-005-9258- 5 1:CAS:528:DC%2BD28XhsVSmsr8%3D 16388408 (Pubitemid 43237859)
34. G Koren Y Kochavi-Atiya Y Bentur NF Olivieri 1991 The effects of subcutaneous deferoxamine administration on renal function in thalassemia major Int J Hematol 54 371 375 1:STN:280:DyaK38%2Fps1Grtg%3D%3D 1756248
35. GJ Kontoghiorghes 2007 Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities Expert Opin Drug Saf. 6 235 239 10.1517/14740338.6.3.235 1:CAS:528:DC%2BD2sXkvV2rt7w%3D 17480173 (Pubitemid 46767631)
36. RJ Bergeron J Wiegand JS McManis JR Vinson H Yao N Bharti, et al. 2006 (S)-4, 5-Dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity J Med Chem 49 2772 2783 10.1021/jm0508944 1:CAS:528:DC%2BD28XjtVygtbc%3D 16640338
37. YS Sohn W Breuer A Munnich ZI Cabantchik 2008 Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications Blood 111 1690 1699 10.1182/blood-2007-07-102335 1:CAS:528:DC%2BD1cXhvFeisrc%3D 17975016 (Pubitemid 351213461)
38. I Gosriwatana O Loreal S Lu P Brissot J Porter RC Hider 1999 Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin Anal Biochem 273 212 220 10.1006/abio.1999.4216 1:CAS:528: DyaK1MXlsFyitrc%3D 10469492 (Pubitemid 29430665)
39. W Breuer A Ronson IN Slotki A Abramov C Hershko ZI Cabantchik 2000 The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation Blood 95 2975 2982 1:CAS:528:DC%2BD3cXivVaqs7o%3D 10779448 (Pubitemid 30235912)
40. BP Esposito W Breuer P Sirankapracha P Pootrakul C Hershko ZI Cabantchik 2003 Labile plasma iron in iron overload: redox activity and susceptibility to chelation Blood 102 2670 2677 10.1182/blood-2003-03-0807 1:CAS:528: DC%2BD3sXnslyku7g%3D 12805056 (Pubitemid 37193611)
41. ZI Cabantchik W Breuer G Zanninelli P Cianciulli 2005 LPI-labile plasma iron in iron overload Best Pract Res Clin Haematol. 18 277 287 10.1016/j.beha.2004.10.003 1:CAS:528:DC%2BD2MXhvVSmtb0%3D 15737890 (Pubitemid 40298370)
42. AC Alfrey DH Froment WS Hammond 1989 Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis Kidney Int 36 753 759 10.1038/ki.1989.259 1:CAS:528:DyaK3cXlvV2m 2615188
43. CM Hershko GM Link AM Konijn ZI Cabantchik 2005 Iron chelation therapy Curr Hematol Rep. 4 110 116 1:CAS:528:DC%2BD28XktVehsw%3D%3D 15720959
44. + transport in distal tubule epithelial cells Wien Klin Wochenschr 109 429 434 1:CAS:528:DyaK2sXksV2hs7s%3D 9261982 (Pubitemid 27319403)
45. JC de Jong PH Willems LP van den Heuvel NV Knoers RJ Bindels 2003 Functional expression of the human thiazide-sensitive NaCl cotransporter in Madin-Darby canine kidney cells J Am Soc Nephrol 14 2428 2435 10.1097/01.ASN.0000089832.52063.F5 14514720 (Pubitemid 37169328)
46. G Link A Pinson C Hershko 1994 Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells Blood 83 2692 2697 1:CAS:528:DyaK2cXmsVGmtLg%3D 8167347 (Pubitemid 24979708)
47. JB Porter 2001 Deferoxamine pharmacokinetics Semin Hematol 38 63 68 10.1016/S0037-1963(01)90061-7 1:CAS:528:DC%2BD3MXhtVegsLk%3D 11206963
48. PE Thuma NF Olivieri GF Mabeza G Biemba D Parry S Zulu, et al. 1998 Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans Am J Trop Med Hyg 58 358 364 1:CAS:528:DyaK1cXis1Wjur8%3D 9546419 (Pubitemid 28160761)
49. S Neuhoff P Artursson I Zamora AL Ungell 2006 Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells Pharm Res 23 350 359 10.1007/s11095-005-9304-3 1:CAS:528:DC%2BD28XhsVSmsrw%3D 16388407 (Pubitemid 43239592)
50. X Alvarez-Hernandez GM Nichols J Glass 1991 Caco-2 cell line: a system for studying intestinal iron transport across epithelial cell monolayers Biochim Biophys Acta 1070 205 208 10.1016/0005-2736(91)90165-5 1:CAS:528:DyaK38XktFOn 1751528
51. S Ferruzza M Scacchi ML Scarino Y Sambuy 2002 Iron and copper alter tight junction permeability in human intestinal Caco-2 cells by distinct mechanisms Toxicol In Vitro 16 399 404 10.1016/S0887-2333(02)00020-6 1:CAS:528: DC%2BD38XltFWisLg%3D 12110278 (Pubitemid 34759983)
52. S Epsztejn H Glickstein V Picard IN Slotki W Breuer C Beaumont, et al. 1999 H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties Blood 94 3593 3603 1:CAS:528:DyaK1MXnsVansro%3D 10552971 (Pubitemid 29536156)
53. PJ Verroust R Kozyraki 2001 The roles of cubilin and megalin, two multiligand receptors, in proximal tubule function: possible implication in the progression of renal disease Curr Opin Nephrol Hypertens 10 33 38 10.1097/00041552-200101000-00006 1:STN:280:DC%2BD3M7jvFWisw%3D%3D 11195049 (Pubitemid 32102220)
54. JE Schnitzer P Oh E Pinney J Allard 1994 Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules J Cell Biol 127 1217 1232 10.1083/jcb.127.5.1217 1:CAS:528:DyaK2cXmslOnu7Y%3D 7525606 (Pubitemid 24362558)
55. U Vogel K Sandvig B van Deurs 1998 Expression of caveolin-1 and polarized formation of invaginated caveolae in Caco-2 and MDCK II cells J Cell Sci 111 825 832 1:CAS:528:DyaK1cXisFSis7g%3D 9472010 (Pubitemid 28163890)
56. B Razani SE Woodman MP Lisanti 2002 Caveolae: from cell biology to animal physiology Pharmacol Rev 54 431 467 10.1124/pr.54.3.431 1:CAS:528: DC%2BD38XotVSmsrw%3D 12223531
57. GJ Anderson DM Frazer SJ Wilkins EM Becker KN Millard TL Murphy, et al. 2002 Relationship between intestinal iron-transporter expression, hepatic hepcidin levels and the control of iron absorption Biochem Soc Trans 30 724 726 10.1042/BST0300724 1:CAS:528:DC%2BD38XntVemt7o%3D 12196177 (Pubitemid 35001639)
58. MW Hentze MU Muckenthaler NC Andrews 2004 Balancing acts: molecular control of mammalian iron metabolism Cell 117 285 297 10.1016/S0092-8674(04) 00343-5 1:CAS:528:DC%2BD2cXjvFemsbg%3D 15109490 (Pubitemid 38534536)
59. J Chung JR Prohaska M Wessling-Resnick 2004 Ferroportin-1 is not upregulated in copper-deficient mice J Nutr 134 517 521 1:CAS:528: DC%2BD2cXitlCru7o%3D 14988440 (Pubitemid 38298489)
60. H Kulaksiz F Theilig S Bachmann SG Gehrke D Rost A Janetzko, et al. 2005 The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney J Endocrinol 184 361 370 10.1677/joe.1.05729 1:CAS:528:DC%2BD2MXhvVeiurw%3D 15684344 (Pubitemid 40340171)
61. N Ishizaka K Saito K Furuta G Matsuzaki K Koike E Noiri, et al. 2007 Angiotensin II-induced regulation of the expression and localization of iron metabolism-related genes in the rat kidney Hypertens Res 30 195 202 10.1291/hypres.30.195 1:CAS:528:DC%2BD2sXlsVKqur8%3D 17460390 (Pubitemid 46541794)